Eris Lifesciences Limited
NSE: ERIS BSE: ERIS
NSE
1,638.30
-13.50 (-0.82%)
Prev Close
1651.8
Open Price
1647.2
Volume
55,563
Today Low / High
1621.8 / 1654.8
52 WK Low / High
977 / 1664.3
Range
1,556 - 1,720
BSE
1,636.80
-17.55 (-1.06%)
Prev Close
1654.35
Open Price
1649
Volume
4,201
Today Low / High
1621.35 / 1651.8
52 WK Low / High
976.9 / 1662
Range
1,555 - 1,719
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1638.3 (target range: 1,556 - 1,720), reflecting a change of -13.5 (-0.81729%). On the BSE, it is listed at 1636.8 (target range: 1,555 - 1,719), showing a change of -17.55 (-1.06084%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Jun
1,647.20
-0.54%
05 Jun
1,605.00
2.92%
04 Jun
1,603.70
0.08%
03 Jun
1,550.10
3.46%
02 Jun
1,555.00
0.71%
30 May
1,618.10
-2.24%
29 May
1,613.00
0.17%
28 May
1,575.80
2.21%
27 May
1,549.90
1.33%
26 May
1,502.40
2.60%
23 May
1,517.00
-0.84%
22 May
1,505.90
0.92%
21 May
1,470.20
2.43%
20 May
1,466.80
0.23%
19 May
1,460.20
-1.13%
16 May
1,488.00
-1.57%
15 May
1,483.90
-0.10%
14 May
1,445.90
2.34%
13 May
1,397.70
3.37%
12 May
1,471.30
-4.51%
09 May
1,450.00
0.41%
Eris Lifesciences Limited Graph
Eris Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Eris Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,638.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,636.80 | 1,653.17 | 1,487.85 - 1,818.48 |
| 1,669.54 | 1,335.63 - 2,003.44 | ||
| 1,685.90 | 1,180.13 - 2,191.68 | ||
| Bearish Scenario | 1,636.80 | 1,620.43 | 1,458.39 - 1,782.48 |
| 1,604.06 | 1,283.25 - 1,924.88 | ||
| 1,587.70 | 1,111.39 - 2,064.00 |
Overview of Eris Lifesciences Limited
ISIN
INE406M01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
209,547
Market Cap
223,111,885,500
Last Dividend
14.7
Official Website
IPO Date
2017-06-30
DCF Diff
585.23
DCF
1,053
Financial Ratios Every Investor Needs
Stock Dividend of ERIS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-13 | February 13, 25 | 7.35 | 7.35 | 2025-02-13 | 2025-03-09 | |
| 2022-08-11 | August 11, 22 | 7.35 | 7.35 | 2022-08-16 | 2022-09-04 | |
| 2021-08-05 | August 05, 21 | 6.01 | 6.01 | 2021-08-06 | 2021-08-28 | |
| 2020-08-13 | August 13, 20 | 5.5 | 5.5 | 2020-08-14 | 2020-09-03 | 2020-08-04 |
| 2020-03-19 | March 19, 20 | 2.87 | 2.87 | 2020-03-20 | 2020-04-10 | 2020-03-05 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,991.30 Cr | 996.68 Cr | 994.62 Cr | 0.4995 | 5.72 Cr | 71.48 Cr | 495.30 Cr | 391.98 Cr | 28.82 | 698.65 Cr | 0.1968 |
| 2023-03-31 | 1,661.82 Cr | 352.35 Cr | 1,309.47 Cr | 0.7880 | 6.10 Cr | 47.18 Cr | 421.66 Cr | 382.16 Cr | 28.10 | 548.08 Cr | 0.2300 |
| 2022-03-31 | 1,326.17 Cr | 260.81 Cr | 1,065.36 Cr | 0.8033 | 32.74 Cr | 50.41 Cr | 424.50 Cr | 406.11 Cr | 29.89 | 511.12 Cr | 0.3062 |
| 2021-03-31 | 1,192.64 Cr | 241.87 Cr | 950.78 Cr | 0.7972 | 5.09 Cr | 43.04 Cr | 387.61 Cr | 355.14 Cr | 26.16 | 439.46 Cr | 0.2978 |
| 2020-03-31 | 1,058.18 Cr | 178.74 Cr | 879.45 Cr | 0.8311 | 4.20 Cr | 35.29 Cr | 321.85 Cr | 296.50 Cr | 21.61 | 383.91 Cr | 0.2802 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 94.14 Cr | 7,048.84 Cr | 3,826.81 Cr | 2,586.1190 Cr | 2,781.27 Cr | 2,687.13 Cr | 189.03 Cr | 534.17 Cr | 20.93 Cr | 1.38 Cr | 15.73 Cr | 2,532.0770 Cr |
| 2023-03-31 | 56.02 Cr | 3,667.33 Cr | 1,446.65 Cr | 2,195.9880 Cr | 876.71 Cr | 820.69 Cr | 131.44 Cr | 377.38 Cr | 103.45 Cr | 8.74 Cr | 6.88 Cr | 443.2330 Cr |
| 2022-03-31 | 50.79 Cr | 2,272.14 Cr | 363.94 Cr | 1,908.3110 Cr | 84.41 Cr | 33.61 Cr | 117.91 Cr | 191.86 Cr | 62.62 Cr | 5.69 Cr | 420.84 Cr | 199.6460 Cr |
| 2021-03-31 | 36.87 Cr | 1,834.78 Cr | 258.36 Cr | 1,576.4210 Cr | 6.78 Cr | -30.09 Cr | 94.47 Cr | 77.88 Cr | 48.74 Cr | 6.11 Cr | 285.92 Cr | 166.9310 Cr |
| 2020-03-31 | 67.21 Cr | 1,552.31 Cr | 255.97 Cr | 1,296.3340 Cr | 12.14 Cr | -55.07 Cr | 69.48 Cr | 87.24 Cr | 42.43 Cr | 8.55 Cr | 3.20 Cr | 164.6900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 486.0050 Cr | -1,854.5220 Cr | 1,379.7790 Cr | 356.8430 Cr | 38.2230 Cr | 94.2450 Cr | -129.1630 Cr | 391.9830 Cr | 1,463.6990 Cr | 0.0000 Cr | -16.9400 Cr |
| 2023-03-31 | 291.7380 Cr | -982.1010 Cr | 688.0250 Cr | -549.6830 Cr | 5.1520 Cr | 56.0220 Cr | -841.4210 Cr | 404.6430 Cr | 817.8000 Cr | -99.9110 Cr | 4.7440 Cr |
| 2022-03-31 | 378.2640 Cr | -319.6100 Cr | -44.6990 Cr | 257.2310 Cr | 13.9550 Cr | 50.8700 Cr | -121.0330 Cr | 442.1980 Cr | 33.5000 Cr | -81.6230 Cr | -23.4450 Cr |
| 2021-03-31 | 375.3610 Cr | -323.3580 Cr | -82.3950 Cr | 349.5980 Cr | -30.3920 Cr | 36.9150 Cr | -25.7630 Cr | 394.4970 Cr | 0.0100 Cr | -74.6790 Cr | -24.9910 Cr |
| 2020-03-31 | 271.1100 Cr | 123.2880 Cr | -334.5910 Cr | 119.8280 Cr | 59.8070 Cr | 67.3070 Cr | -151.2820 Cr | 331.3500 Cr | -8.6020 Cr | -46.9790 Cr | 13.1780 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 722.12 Cr | 176.88 Cr | 545.24 Cr | 0.7551 | 169.11 Cr | 83.63 Cr | 6.15 | 254.53 Cr | 0.1158 |
| 2024-09-30 | 741.17 Cr | 392.38 Cr | 348.79 Cr | 0.4706 | 184.03 Cr | 91.59 Cr | 6.73 | 269.06 Cr | 0.1236 |
| 2024-06-30 | 719.72 Cr | 389.15 Cr | 330.57 Cr | 0.4593 | 174.05 Cr | 83.18 Cr | 6.11 | 251.63 Cr | 0.1156 |
| 2024-03-31 | 550.93 Cr | 274.56 Cr | 276.37 Cr | 0.5016 | 94.53 Cr | 70.96 Cr | 5.22 | 163.58 Cr | 0.1288 |
| 2023-12-31 | 483.48 Cr | 88.87 Cr | 394.61 Cr | 0.8162 | 133.99 Cr | 102.74 Cr | 7.55 | 179.71 Cr | 0.2125 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 150.02 Cr | 96.40 Cr | 246.42 Cr | 567.50 Cr | 256.28 Cr | 1,317.66 Cr | 520.44 Cr | 7,021.88 Cr | 3,844.73 Cr |
| 2024-06-30 | -1,400.63 Cr | 2,801.26 Cr | 1,400.63 Cr | 0.00 Cr | 0.00 Cr | 1,400.63 Cr | 0.00 Cr | 0.00 Cr | -3,222.03 Cr |
| 2024-03-31 | 1,400.63 Cr | 0.00 Cr | 1,400.63 Cr | 422.02 Cr | 189.03 Cr | 2,302.07 Cr | 523.65 Cr | 7,048.84 Cr | 3,826.81 Cr |
| 2023-12-31 | -190.62 Cr | 381.25 Cr | 190.62 Cr | 0.00 Cr | 0.00 Cr | 190.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 172.71 Cr | 19.52 Cr | 192.23 Cr | 349.75 Cr | 139.09 Cr | 961.15 Cr | 422.46 Cr | 3,875.19 Cr | 1,447.62 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 83.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 70.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 102.74 Cr | 91.43 Cr | 0.00 Cr | 0.00 Cr | 91.43 Cr | 264.15 Cr | 172.71 Cr | 0.00 Cr | 91.43 Cr |
| 2023-09-30 | 123.43 Cr | 84.19 Cr | 0.00 Cr | 0.00 Cr | 84.19 Cr | 172.71 Cr | 88.53 Cr | 0.00 Cr | 84.19 Cr |
| 2023-06-30 | 94.86 Cr | 81.79 Cr | 0.00 Cr | 0.00 Cr | 81.79 Cr | 137.81 Cr | 56.02 Cr | 0.00 Cr | 81.79 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Chief Financial Officer
Mr. Sachin Shah
Gender: male
Year Born: 1980
Senior Vice President
Mr. Deepak Kapoor
Gender: male
Year Born: 1964
President Medical
Mr. Vijay S. Joshi
Gender: male
Year Born: 1953
Chairman & MD
Mr. Amit Indubhushan Bakshi
Gender: male
Year Born: 1975
Compliance Officer & Company Secretary
Mr. Milind Talegaonkar
Gender: male
Year Born:
Executive Director & Chief Operating Officer
Mr. Krishnakumar Vaidyanathan
Gender: male
Year Born: 1974
Executive Director
Mr. Inderjeet Singh Negi
Gender: male
Year Born: 1971
Vice President
Mr. Manish Kapoor
Gender: male
Year Born: 1977
President of Sales & Marketing
Mr. Gagan Atreja
Gender: male
Year Born: 1968
Whole Time Director
Mr. Kaushal Kamlesh Shah
Gender: male
Year Born: 1979
FAQs about Eris Lifesciences Limited
Who is the CEO of the company?
The CEO is Mr. Amit Indubhushan Bakshi.
What is the current market price of the stock?
The current price is ₹1,638.30.
What is the 52-week price range?
The range is ₹977-1664.3.
What is the market capitalization of the company?
The market capitalization is ₹22,311.19 crores.
What is the dividend yield?
The dividend yield is 0.45%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 67.64.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Eris Lifesciences Limited (ISIN: INE406M01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹22,311.19 crores and an average daily volume of 209,547 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹14.7.